The enterohormones by Vinik, A.I.
23 February 1974 S.A. MEDICAL JOURNAL
The Enterohormones




In this review, the origin of endocrinology has been traced
to the discovery of the first hormone, secretin, a gut hor-
mone, by Bayliss and Starling 70 years ago. Since then
gastro-enterological endocrinology has flourished with the
discovery of a host of new hormones, including glucagon,
enteroglucagon, gastrin, cholecystokinin-pancreozymin
(CCK-PZ), gastro-intestinal inhibitory peptide (GIP), vaso-
active intestinal peptide (VIP), motilin, and many others
are awaiting discovery.
There is extensive overlap in the biological and immuno-
logical activity of these hormones which may be related
to similarities in primary structure, a common ancestral
molecular origin or relative non-specificity of the receptor
sites in various target organs.
Administered gut hormones have proved useful in the
diagnosis of many endocrine and non-endocrine disorders,
and provide scope for the medical management of con-
ditions hitherto considered to be primarily surgical.
Measurements of circulating levels have given us a
deeper understanding of physiological and pathophysiolo-
gical processes, and in many instances are the simplest
and most rapid means of diagnosing certain disease
processes.
The review was intended to assist the busy practitioner
to keep abreast of a rapidly-advancing field where new
ideas and concepts appear at such a breathtaking rate
that only the individual intimately concerned can keep
pace. The author hopes to have at least achieved this
objective.
5. Air. Med. J. o 48, 359 (1974).
mSTORICAL
'It was a great afternoon', according to Sir C. J. Martin.'
In the laboratory at University College he had watched
Bayliss and Starling denervate the jejunal loop of an
anaesthetised dog and put a small amount of weak hydro-
cWoric acid into its colon. When pancreatic juice flowed,
Starling realised 'it must be a chemical reflex'. A great
afternoon it certainly was, for it marked the start of a new
biological discipline, endocrinology.'
Endocrinology had its birth with a gut hormone. Fol-
lowing a rather long silent period, recent years have seen
a veritable explosion in the area of gut hormones which
will be reviewed.
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After 14 years of work Mutt and Jorpes,3 in 1966,
described the molecular structure of the hormone and in
the same year Bodanszky et al.' synthesised secretin. In
1905 Edkins5 proposed that a substance may be separated
from cells of the mucous membrane which, when passing
into blood or lymph, later stimulates the secretory cells of
the stomach to functional activity. It was not until 1938
that Komarov' distinguished this material from histamine
and termed it gastrin. In 1942 Uvnas' demonstrated that
vagal impulse released gastrin, and the role of gastrin in
gastric acid secretion was firmly established. The charac-
terisation and chemical structure of gastrin in 1964 by
Gregory and colleagues' opened the modern era of the
study of gastrin.
Fifty years ago Murlin et al.' discovered a hyperglycae-
mic contaminant of partially purified insulin. His observa-
tions were soon confirmed.'· This hyperglycaemic factor
was termed glucagon and it was only in 1956 that Bromer
et al." finally elucidated the structure of this molecule.
This was soon followed by the synthesis of this hormone
by Wlinsch and Weinges."
Cholecystokinin followed in 1928 and pancreozymin was
isolated by Harper and Raper" in 1943. Cholecystokinin
and pancreozymin (CCK-PZ) were shown to be one and
the same hormone by Jorpes14 in 1968, and were synthesised
by Ondetti et al.' in the same year. Sutherland and De Duve"
in 1948 found hyperglycaemic activity of extracts of small
intestine and postulated the existence of a hormone akin
to pancreatic glucagon. Unger et aC', as recently as 1968,
established the secretion of gut glucagon-like material into
the portal circulation of dogs, but as yet the nature and
structure of these moledues have not been identified. More
recently, in this decade, further hormones have been added
to this list, induding GIP (gastro-intestinal inhibitory pep-
tide, VIP vaso-active intestinal polypeptide), and motitin.
The biological actions of gastrin and secretin have been
reviewed'·18 and only pertinent aspects will be dealt with
here.
OVERLAP IN EXOCRINE ACTIONS
Gastrin increases gastric acid secretion as its primary
action and CCK accomplishes this as well. Similarly, CCK
increase gall bladder contraction as its primary action and
elicits an enzyme-rich fluid from the pancreas, effects
shared by gastrin albeit in the case of the gall bladder, at
a pharmacological dose. Furthermore, for pancreatic
secretion of both bicarbonate and enzymes, gastrin aug-
ments CCK-PZ while the two hormones competitively in-
hibit each other with regard to hydrogen ion secretion by
the stomach.
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The molecular similarity between glucagon and secretin
is also reflected in their functional similarity; both mole-
cules inhibit gastric acid secretion and gastric motility.
However, while secretin stimulates gastric pepsin secretion
in man, the effect of glucagon is unclear. Glucagon has no
effect on the basal pepsin production but inhibits histamine-
stimulated release of pepsin. Glucagon and secretin are
capable of enhancing the action, as seen in increased bile
flow and output of sodium chloride and bicarbonate when
the two hormones are administered together. Both hor-
mones stimulate secretion of Brunner's glands in dogs and
reduce the motility of intestine in man. In addition, the
hormones release insulin from the pancreas and cause
glycolysis in isolated fat cells. On the other hand, althoug.h
olucaoon does not alter basal pancreatic enzymes and bl-
~arbo~ate secretion, it is capable of markedly inhibiting
secretin-induced secretion although, somewhat surprisingly,
the output of enzymes falls more than that of bicarbonate.'
If one compares the action of secretin and glucagon to
that of gastrin and CCK, one again notices overlap in
action between the two sets of hormones and again it may
be seen that there are examples of competitive inhibition
and competitive augmentation. Thus, secretin alone has no
effect on gall bladder contraction but augments the action
of CCK and non-competitively inhibits CCK or gastrin-
stimulated acid secretion and shows non-competitive aug-
mentation with gastrin or CCK on pancreatic bicarbonate
and enzyme secretion.
OVERLAP IN ENDOCRINE ACTIONS
The diabetologists' and endocrinologists' interest in gut hor-
mones dates to the observations in 1902 by Moore et al.'"
that feeding acid alcohol duodenal extracts lowered blood
glucose in diabetic dogs. In 1954 Scow and Cornfield'·
found that glucose was removed more rapidly from the
blood of rats when the dose was administered orally, than
when injected intravenously. In 1964 McIntyre et al." and
Elrich et al." attributed the more rapid removal of oral
glucose to the augmented insulin secretion seen after the
oral dose. This enhancement of insulin release was not
abolished by portacaval anastomosis," suggesting that the
higher levels of insulin and enhanced glucose tolerance
following absorption of glucose from the gut were due
to an intestinal factor, possibly a hormone, and thus
confirming the earlier observations by La Barre and Shill"
who showed that the intravenous injection of a duodeno-
jejunal extract into dogs, caused hypoglycaemia mediated
by the pancreas. La Barre suggested the name 'incretin'
for this intestinal factor, and as yet the nature of this
material has not been resolved. Several of the hormones
released from the intestinal mucosa are capable of stimu-
lating insulin release. The main candidates have been
secretin, CCK, gut glucagon and gastrin, while GIP has
now entered this arena.
The rise in circulating gut glucagon-like material, after
the ingestion of oral glucose, has been demonstrated by
Unger et al." Gut glucagon has been shown to promote
insulin release from the pancreas and could therefore be
the material referred to as incretin. However, the physio-
logical significance of gut glucagon secretion in relation
to insulin output is uncertain."
Secretin is another contender for this role. Ingestion of
glucose causes a rapid and large increase in circulating
secretin-like material''' and, as referred to earlier, secretin
causes a marked increase in insulin release from the
pancreas."'" Furthermore, secretin potentiates the glucose
or amino acid-stimulated insulin secretion.'·'" However,
the physiological relevance of these observations still re-
mains in doubt, since instillation of hydrochloric acid into
the duodenum, which elicits a rise in circulating secretin,
does not consistently increase insulin secretion."""'" Final·
Iy, it has been suggested that the release of insulin by the
pancreas after secretin stimulation requires the integrity of
the exocrine pancreas."
The third candidate for this function, CCK·PZ, appears
to release insulin independently of the integrity of the exo·
crine pancreas. In addition CCK-PZ is the only gastro·
intestinal hormone that has been shown to stimulate gluca-
gon release from the pancreas," thus CCK-PZ could act
as a stimulus for insulin secretion by a dual mechanism,
firstly by direct stimulation and secondly by the release
of pancreatic glucagon. More recently, however, highly
purified CCK-PZ has been shown to be devoid of insulo·
genic activity - which could be attributed to the con-
taminating GIP content.
Gastrin has also been shown to release insulin from
the pancreas directly, but only in pharmacological
amounts. Furthermore, we have presented evidence mili-
tating against a physiological role for gastrin in initiating
insulin secretion. Nevertheless, it is clear that gut glucagon,
secretin, CCK·PZ, GIP and probably gastrin, may all
fulfil the role of a hypothetical hormone 'incretin' and act
as signals for the release of insulin on the arrival of food
in the gastro-intestinal tract. Such an action would fulfil
a physiological need and anticipate the presentation of
food substrate into the cirCUlation, and so minimise large
unphysiological fluctuation in plasma substrate levels. Since
these hormones not only release insulin, but interact with
each other - for example gastrin serves as a direct
stimulus to the release of secretin and, vice versa, secretin
may inhibit gastrin release - it is clear that this role is
subserved by more than one hormone and that 'incretin'
is not a hormone but rather a concept involving multiple
hormones interacting with each 'other upon insulin secretion
from the pancreas.
Grossman" has. postulated from the above findings that
gastrin, CCK, secretin, and probably glucagon, act on one
receptor. The receptor is said to have two interacting sites,
one with an affinity for the chemically related gastrin and
CCK and another for secretin and the similar glucagon.
His hypothesis predicts that all target organs that react
with one of these hormones will react to the other two,
and predictably glucagon as well. Simultaneous action of
the two hormones leads to competitive or non-competitive
augmentation or inhibition, depending upon whether the
hormones are acting on the same or different interaction
sites and whether the hormones acting on the receptor are
stim~latory or inhibitory. In other words, if both hormones
have a stimulatory action at a particular site, then in cop-
cert they will non-competitively augment each other. If one
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hormone has an inhibitory action, and the other a stimu-
latory action at a particular site, they will then competi-
tively antagonise each other's action. It appears that
glucagon will act at these receptor sites in very much the
same way. However, one difference which emerges is the
fact that glucagon has glycogenolytic and gluconeogenic
properties' which are not shared by the other gastro-
intestinal hormones, although even this is open to some
doubt. 35
PRIMARY STRUCTURAL SIMILARITIES
The question which arises is why these hormones have
such tremendous overlap in both their endocrine and exo-
crine functions.
TABLE I


















Synthet. octapeptide from CCK-PZ (mol wt 1 143)
Asp-Tyr-Met-Gly-Try-Met-Asp-Phe-NH2
S'03
Gastrin I (human) (mol. wt 2 200)
Pyr-Gly-Pro-Try-Leu-Glu-Glu-G lu-GIu-Glu-Ala-Tyr-G/y-Tyr-
Met-Asp-Phe-NH2
Gastrin 11 (human) (mol. wt 2 280)
Pyr-Gly-Pro-Try-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-
Gly-Try-Met-Asp-Phe-NH2 S'03
Gastrin pentapeptide (ICI) (mol. wt 653)
Gly-Try-Met-·Asp-Phe-NH2
Caerulein (mol. wt 1 258)
Pyr-GI n-Asp-Tyr-Thr-Gly-Try-Met-Asp-Phe-NH2
S'03
Examination of the primary structure of these hor-
mones (Table n provides us with a clue. Comparing the
C terminus of the peptide of cholecystokinin-pancreozy-
min with that of human gastrin, one notes an identical
pentapeptide in the two molecules. It is of interest that
this pentapeptide has also been found to occur in a de-
capeptide caerulein isolated by Erspamer ei al.'" from the
skin of the Australian frog Hyla caerulea. Furthermore,
this small pentapeptide, pentagastrin, has all the biological
properties of human gastrin, although at a higher molar
concentration, and a comparison of the homology of secre-
tin and glucagon reveals that 14 of the 27 amino acids in
secretin are identical in position to those of the 29 amino
acids of glucagon. Comparing Brown's enterogastrone,
which is probably GIP, with glucagon and secretin, one
is again struck by the tremendous overlap in primary
structure of the three hormones. It is apparent that gastrin
and CCK, with their shared primary structure, have a
broad spectrum of action on many different glands and
muscles and act essentially on the same targets with only
a few exceptions.
ORIGIN, ERA AND SPECIES OF GUT
HORMONES
Is this complex interaction between these hormones a
question of chance, or is there some anatomical, embryo-
logical or other reason? Gastrin has been isolated from
the gastric antral mucosa, and CCK-PZ, secretin and gut
glucagon from the small intestinal mucosa. Furthermore,
these hormones, or cells producing these hormones, have
been found in the pancreas as well. The endocrine glands
are usually described as being derived from all three
germinal layers: firstly, ectodermal derivatives including
the pituitary and adrenal medulla; secondly, endodermal
or foregut derivatives including the parathyroid, thyroid,
pancreatic islets and the ultimobranchial body; and thirdly,
those from the nephrogenic ridge, the ovary, testis and
adrenal cortex which are thought to be mesodermal in
origin. The developmental, histological and biochemical
similarities of the peptide-secreting endocrine glands·, the
frequent occurrence of multiple endocrine tumours of these
glands, and the frequent production of peptide hormones
by non-endocrine foregut derivatives, suggest that the
ectodermal and endodermal endocrine glands are related
through a common stem cell precursor in the foregut
mucosa.
These cells are probably neuro-ectodermal in origin
and migrate into the primitive alimentary tract in which
they form the enterochromaffin system and are carried,
with the buds of the various endocrine glands, to their
resting places in the anterior pituitary, thyroid, parathy-
roid, islets of Langerhans, ultimobranchial body and
thymus. They also form the chromaffin system, the adrenal
medulla and the ganglia of the autonomic nervous system
and the chemoreceptor system which are present in the
hypothalamus and give rise to the posterior pituitary
hormones."
Employing a method which depends on the production
from an exogenous percursor of an amine which is
stored in specific granules and which is convertible
by treatment with hot formaldehyde vapour into a
fluorescent derivative, Pearse and Polak3S have demon-
strated the neuro-ectodermal origin of these endocrine-
secreting cells in the gut and pancreas. These cells have
been referred as the APUD-FIF series and have been
found in the gut and in the pancreas. Included among
these are the C cells of the thyroid gland known to secrete
thyrocalcitonin. For instance the C cells of the ultimo-
branchial body ultimately produce thyrocalcitonin while
the pyloric G cells produce gastrin. It is, however, less
easy to see how cells of a single type, sharing the same
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environment, are modified to produce a number of dif-
ferent hormones, even as in the case indicated above, their
primary structures contain identical amino acid sequences.
Nevertheless, to quote Polak," 'the APUD-FIF cells ap-
pear to be brothers under the skin and it is perhaps not
surprising that they appear to recognise and to respond
to each others products'.
If one examines the origin, era and species of these
hormones, further light can be shed on this matter. Secre-
tin, for example, has been found in the intestine of
amphibia and elasmobranchs suggesting a mid-palaeozoic
origin approximately 300 million years ago. It has also
been found in birds, reptiles and teleost fish and in all
mammals studied." Similarly, gut glucagon has been iso-
lated from a number of cold-blooded vertebrate species,
including the eel, frog and tortoise, and from lower inver-
tebrate species,"" although in the latter the exact origin of
the material remains obscure since the whole animals
were extracted. Pearse and Polak'" identified cells in the
gastro-intestinal mucosa excluding the pylorus and duo-
denum, and which were most numerous in the fundus and
the mid- and terminal jejunum, which they termed entero-
glucagon cells (EG cells). "
Thus there is phylogenetic, embryological, morphologi-
cal, pathophysiological and biochemical evidence in terms
of primary structural similarity, of a common origin of
these hormones. This renders it somewhat easier to under-
stand the complex nature of the interaction between these
hormones and their shared functional activity. What re-
mains a little more difficult to comprehend is what their
original function was, and how they become individually
regulated in the advanced Homo sapiens.
With regard to the first, I propose that these hormon"es
arose from a common ancestor molecule, say some 300
million years ago and subserved a function entirely un-
related to their present function. As an example we have
parathyroid hormone which is present in invertebrates and
therefore cannot be responsible for regulation of calcium
homeostasis in bone, and it is clear that at some stage it
was a hormone primarily concerned with regulation of
acid-base balance. These hormones, we know, are markedly
elevated in hyperosmolar syndromes and are also respon-
sible for the marked outpouring of fluid into the gastro-
intestinal tract. It is possible that at some stage they served
a primary role of regulating acid-base and water and
electrolyte metabolism, and with evolution have come to
function in a more refined capacity. It seems that the
gut represents a massive endocrine organ which anticipates
the arrival of substrate and so activates each of the other
endocrine glands in turn. For example, glucagon is known
to stimulate pituitary growth hormone secretion, or alter-
natively thyrocalcitonin output from the C cells of the
parathyroid, and thirdly insulin secretion from the pan-
creas. We once regarded the pituitary gland as the director
of the endocrine orchestra and some schools have now
suggested that the hypothalamus has replaced the pituitary
gland in this capacity. I suggest that we should look at the
gut as an endocrine organ which is the primary dictator in
the sequence of events determined by endocrine activity.
The second proposal, or the second problem, poses
some difficulty. There are three possibilities which come
to mind, firstly that local nervous and humoral factors
determine the release of a specific hormone at a specific
site; secondly that only parts of the parent ancestral
molecule are synthesised and released from a particular
tissue which retains the capacity, under certain circum-
stances, to revert to its former nature and produce the
parent molecule and related molecules; and thirdly that
these cells are under the influence of some other regula-
tory glands, for example the pituitary. It is known, for
example, that in acromegaly with over-secretion of growth
hormone, the pancreas over-secretes glucagon arid possibly
gastrin, which suggests the presence of an entero-endocrine
and pituitary-entero feedback system.
ADMINISTERED GASTRO·INTESTINAL
HORMONES IN DIAGNOSIS
Gastrin is the preferred stimulant for routine gastric
secretory testing because it produces the same maximal
response as histamine or betazole but with almost none
of the unpleasant side-effects. Since pentagastrin, the ter-
minal pentapeptide of gastrin (leI), is more readily avail-
able, it is usually used. It has all the actions of gastrin but
is less potent.
Secretin is used in diagnostic pancreatic secretory tests
and since no fraction of the molecule is biologically active,
the whole molecule must be used. Pure porcine secretin
as the natural product is employed, because synthetic secre-
tin is in very short supply.
CCK - PZ is useful for contracting the gall bladder and
demonstrating the biliary ducts during cholecystography.
In theory CCK - PZ should be superior to the traditional
fatty meal, because it does not depend on the vagaries of
gastric emptying and the variable ability of the intestine
to release CCK - PZ in response to fat. The minimal frag-
ment of CCK with the biological actions of the whole
molecule is the carboxyterminal heptapeptide-amide which
contains the minimal fragment of gastrin. This minimal
fragment is more potent than the whole molecule and has
all the actions of CCK - PZ, as does the substance caeru-
lein; CCK - PZ has also been used to test pancreatic func-
tion. When CCK - PZ a~d secretin are given together
they markedly augment the enzyme-stimulating action of
CCK - PZ, and conversely CCK - PZ, a primary stimulant
of enzymes acting with secretin, markedly augments secre-
tin bicarbonate-stimulating action, and when given to-
gether, they improve the diagnostic discrimination in
clinical pancreatic secretory tests.
Glucagon, which is available as pure pancreatic gluca-
gon, has been established as a test for virtually every en-
docrine dysfunction syndrome. Firstly, since it provides the
release of catecholamines from the adrenal medulla it is
used for the diagnosis of phaeochromocytoma, and second-
ly, it is a potent stimulant of the thyroid C cells and has
been of use in the diagnosis of medullary carcinoma of the
thyroid. Thirdly, it is a potent neoglucogenic and .glyco-
"genolytic hormone and is useful in the diagnosis of
chronic liver disease. The pituitary is stimulated to release
growth hormones and glucagon is used as a diagnostic'
test of pituitary insufficiency. Finally, glucagon is safer
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than tolbutamide in eliciting insulin secretion from an in-
sulinoma and has been used with some success in the diag-
nosis of this tumour.
THERAPEUTIC USES OF GUT
HORMONES
Since secretin stimulates pancreatic production of highly
alkaline juice and increased bicarbonate secretion from
the liver, hepatic bile, Brunner's glands, and weakly inhi-
bits gastric acid production and suppresses gastrin release,
it has been proposed as a possible therapeutic measure for
peptic ulceration, and duodenal ulcer. Certainly in rats,
simultaneous administration of secretin prevents the hyper-
plasia of parietal cells that occur during long-term dosage
with pentagastrin. It may be that when a long-acting
synthetic analogue of secretin is available, it could cause
hypoplasia of parietal cells and produce a medical
gastrectomy.
CCK - PZ and related peptides are such powerful stimu-
lants of propulsive motility in the large and small gut
that they may be of considerable use in paralytic ileus.
Caerulein also falls into this category. CCK - PZ and
related peptides are also powerful relaxants of the sphinc-
ter of Oddi and one ought to give consideration to the
use of this peptide in the treatment of biliary colic and of
stones in the common duct after cholecystectomy.
Therapeutically, long-acting glucagon is valuable in the
treatment of some hypoglycaemic disorders; especially
when there is difficulty in administering glucose intraven-
ously or by mouth, glucagon subcutaneously provides
fairly prompt relief of the hypoglycaemia.
More recently Knight et al:' have proposed that in acute
pancreatitis, glucagon is secreted, which in turn suppresses
pancreatic exocrine function; this prevents the outpouring
and release of inordinate amounts of enzymes responsible
for the gross destruction seen in pancreatitis. When the
serum glucagon level falls, haemorrhagic or necrotic pan-
creatitis sets in. They have suggested that this complication
can be averted by continuous administration of glucagon.
At present such a trial is underway in this hospital and we
await with interest the results thereof.
There have been further suggestions that glucagon is
causally related to the inevitable increase in tissue protein
breakdown that follows severe injuries and major opera-
tions. It becomes theoretically possible that when glucagon
analogues are available which compete with glucagon, or
alternatively secretin, which is structurally similar, and
which may competitively antagonise the action of glucagon
in this respect, these will be of use in the prevention of
the severe protein breakdown and tissue destruction
which occurs in the postoperative or post-traumatic state.
It has been suggested on the basis of the ability of
exogenous glucagon to reduce plasma cholesterol and
triglyceride levels that this hormone may be of some use
in the prophylaxis of myocardial infarction resulting from
generalised atheroma. This hormone has also won some
favour in the treatment of refractory congestive cardiac
failure, since it increases the rate and force of contraction
of the myocardium.""
CIRCULATING LEVELS IN DIAGNOSIS
The prime and already classic example of involvement
of the gut hormones in the pathogenesis of disease is the
Zollinger-Ellison syndrome with three cardinal features:
fulminating peptic ulcer, massive secretion of acid by the
stomach, and islet cell tumours of the pancreas which do
not arise in the beta cells and do not secrete insulin.
Until recently the diagnosis of the Zollinger-Ellison
syndrome has depended upon the demonstration of mas-
sive gastric hypersecretion. An overnight 12-hour gastric
aspiration should yield more than I 000 ml of fluid con-
taining more than 100 mEq of acid. The basal acid secre-
tion should be very high and approach the levels obtained
after administering pentagastrin, so that little increase
occurs on maximal stimulation. The clinching of the diag-
nosis is the finding of a high fasting level of serum gastrin,
provided that pernicious anaemia has been excluded.
Gastrin levels should also be measured in all patients who
have severe ulcer symptoms, unexplained diarrhoea, or
multiple endocrine abnormalities, since the Zollinger-
Ellison syndrome has been reported as pan of the MEA
syndrome, including adenomata of the parathyroid, pitui-
tary and carcinoid syndromes. We have measured gastrin
levels in one patient with medullary carcinoma of the
thyroid, and it would appear that these are elevated and
hence would add yet another multiple endocrine abnor-
mality syndrome.
Recently Polak et al." divided patients with these
syndromes into two groups on the basis of immunofluores-
cent, immunochemical and ultrastructural findings. In the
first group, type I disease, the patient has a short history,
very high levels of serum gastrin, profound hyperplasia of
the gastrin-secreting G cells in the gastric antrum, and a
normal pancreas. Patients with type II disease have longer
histories, less extreme hypergastrinaemia, a normal popu-
lation of antral G cells, but hyperplasia or frank tumour
of the pancreatic islets. This has important implications
in management because patients with type I disease should
be cured with a lesser operation than total gastrectomy;
in fact a patient has been reported where vagotomy and
antrectomy abolished the symptoms and serum gastrin
levels returned to normal within 2 months. It is also im-
portant to note in this context that we can now recognise
a new type of gastric tumour arising from antral G cells
which may mimic Zollinger-Ellison syndrome and require
only resection of the secretory tumour of the stomach....
Another syndrome in which an islet cell tumour of the
pancreas has been implicated as a cause of diarrhoea,
is the WDHA syndrome which represents watery diarrhoea,
hypokalaemia with acidosis and achlorhydria. The diar-
rhoea may be so severe as to warrant the name pancreatic
cholera, but since the term WDHA originated in this
school, we prefer to adhere to that." Elias et al.... have now
produced evidence that the syndrome is caused by over-
production of an enterogastrone, namely GIP, and latterly
revised this to include VIP. It seems, therefore. that the
known syndromes associated with overproduction of in-
testinal hormones may only represent the tip of an iceberg,
the remainder of which remains to be exposed. No doubt
measurement of gut hormones in all cases of multiple
endocrine adenomatosis, and in patients with strange
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diarrhoeic syndromes will reveal further examples of over-
secretion of gut hormones.
Serum gastrin measurements in patients with ordinary
duodenal ulcer and gastric ulcer are less clear. One would
expect duodenal ulcer patients to show raised levels of
gastrin, and gastric ulcer patients to have depressed levels,
but this is not the case. The explanation is simple: acid
secretion reflexly inhibits the release of gastrin so that in
duodenal ulcer patients the levels are frequently lower
than those in gastric ulcers. An extension of this reflex
arc is the fact that in patients with atrophic gastritis, or
in pernicious anaemia patients who have acWorhydria,
gastrin levels may be markedly elevated. This does not
imply that gastrin is not implicated in the causation of
duodenal ulcer for it appears that if one neutralises
gastric acid secretion, the duodenal ulcer patient has the
ability to hyper-respond and markedly elevate circulating
gastrin concentration, while the gastric ulcer patient is
secreting gastrin at the maximal rate. We propose to de-
velop a bicarbonate tolerance test to neutralise gastric
acid secretion and measure gastrin in the basal and stimu-
lated states. Postoperatively, measurements of gastrin levels
provide an excellent index of the effectiveness of gastrec-
tomy, since levels fall to the undetectabIe zone. Also,
when truncal vagotomy has been the procedure, and the
antrum has been left intact, the basal gastrin level becomes
markedly elevated, four to five times that of the normal
untreated patient, and it is a useful marker of the effective-
ness of the vagotomy.
Enteroglucagon measurements are useful in patients
who present with reactive hypoglycaemia. There has been
a problem in differentiating patients with reactive hypo-
glycaemia from those with islet cell tumour secreting in-
sulin. It seems now that the reactive hypoglycaemic patient
does not oversecrete insulin in response to, say, a meal or
a glucose load, but rather oversecretes enteroglucagon. It
has been suggested that the enteroglucagon competes with
glucagon at the receptor sites in the liver and thus inhibits
hepatic glycogenolysis and neoglucogenesis, resulting in de-
creased hepatic glucose output with a marked fall in blood
sugar concentrations."
In conclusion, I quote Professor Bank: 'Endocrinology
which was born with a flourish in the gastro-intestinal tract
with the discovery of the first hormone, secretin, has re-
turned to roost, and the place of the gastro-intestinal endo-
crinologist is assured'.
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